The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Executes the first project for developing and manufacturing a novel anticancer mAb
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Construction is now underway with the facility scheduled to be operational by 2025
Syngene's collaboration with Zoetis started in 2011
Both manufacturing facilities are based out of Benguluru, India
Subscribe To Our Newsletter & Stay Updated
